Tagged with Manufacturing,

Morocco Karim Lahlou of Moroccan pharma manufacturer Iberma discusses the firm’s evolution in recent years, the abundant opportunities for Iberma in the African market, and why strong international partnerships will help the company thrive in the future.   While we continue developing new business ideas, we are capitalizing on our stable…

USA So far in 2020 PharmaBoardroom has conducted interviews with several key stakeholders in US healthcare. We have heard from leaders the US FDA, as well as representatives of patient groups, health insurance providers, and firms operating in the US on what they consider the most pressing issues facing US healthcare.…

Morocco In 2020, PharmaBoardroom has met with stakeholders from across the Moroccan healthcare and life sciences industries. These interviewees range from general managers overseeing several countries in the region from a base in Morocco to association heads and key opinion leaders from the worlds of academia and policymaking. Several recurring themes…

Morocco Ali Besri, Pfizer Morocco GM and North Africa Lead reveals the importance of Morocco’s stability and assets allowing the country to be recognized internationally for its manufacturing investments and capabilities and highlights how Pfizer has capitalized on this with a footprint in the country for over half a century. Looking…

Russia Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association and new breakthroughs in Coronavirus diagnostics.   Government amends legislation around emergency response to diseases The State Duma, as is…

Czech Republic In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working almost 30 years previously.   My goal is to continue reinvesting our profits to keep growing and leave behind a…

Romania Cătălin Vicol introduces Biofarm, a leading Romanian pharma producer on the verge of significant international expansion. Vicol shares his insights on the potential of the Romanian consumer healthcare (CHC) market, which accounts for 95 percent of Biofarm’s activities, and discloses his ambition of becoming the number one CHC pharmaceutical producer…

Morocco Multinational pharmaceutical companies are increasingly seeing Morocco as a top manufacturing destination for the African continent. Firms from Europe, Asia-Pacific and the US are investing millions of dollars in bolstering and expanding their drug production facilities in the North African nation thanks to its strategic location, price-competitiveness, and comparatively developed…

Morocco A new IQVIA study sponsored by LEMM, the Moroccan association of multinationals looked at 3,437 references sold on the private market, which represents 75 percent of the total pharma market, and shows that eight out of ten drugs on the Moroccan market are produced locally. Made with Visme Infographic Maker…

Morocco Ensuring the country’s “sanitary sovereignty” has long been a key policy for Morocco and its government. In order to encourage the local production of drugs, Law 17-04 was promulgated in 2006 requiring pharma companies to operate a manufacturing, control and storage site in order to apply for marketing authorization.  …

Belgium Luxembourg Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home to the company’s Heist-op-den-Berg production facility, a key manufacturing site for the global group. Vanneste delivers a strong message about…

Mexico Juan de Villafranca, executive director of the Asociacion Mexicana de Laboratorios Farmaceuticos (AMELAF), shares the exciting new initiatives he has launched in the past two years of his term; the importance and strength of AMELAF as the representative association of 44 100 percent Mexican-owned pharmaceutical manufacturers; and the potential and…